DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
Horizon Therapeutics plc today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to placebo. The results support prior analyses of significant reductions in inflammation, proptosis (eye bulging) and diplopia (double vision), as well as improvements in quality of life (QoL). These data were presented at the 89th Annual Meeting of the American Thyroid Association (ATA). This is the first presentation of the pooled analyses and builds on the individual positive results of the Phase 2 and Phase 3 clinical studies.
Teprotumumab is an investigational medicine and its safety and efficacy have not been established. The teprotumumab Biologics License Application (BLA) was granted Priority Review by the U.S. Food and Drug Administration (FDA) and if approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020.
News & MeetingsTEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
News & MeetingsNew Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durabil...Horizon Therapeutics plc announced posit...
News & MeetingsTeprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 StudyResults from the phase 3 OPTIC study sho...
Evidence & EducationEarly Experience With Teprotumumab for Chronic Thyroid Eye DiseasePurpose: To report the first case of a ...
News & MeetingsTeprotumumab Significantly Improves Proptosis in Thyroid eye DiseasePatients with thyroid eye disease treate...
News & MeetingsHorizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application...Horizon Therapeutics plc today announced...
News & MeetingsHorizon Therapeutics plc Reports Strong Third-Quarter 2019 ResultsHorizon Therapeutics plc today announced...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.